Related Experiment Videos
Cyclosporin-A induced heart failure after orthotopic heart transplantation
Insights
Two heart transplant patients developed heart failure due to Cyclosporin-A toxicity, not rejection. Prompt withdrawal of Cyclosporin-A and alternative immunosuppression led to recovery, highlighting drug-induced complications in heart transplantation.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Dilated cardiomyopathy (CMP) necessitates orthotopic heart transplantation (HTX).
- Standard immunosuppression protocols involve Cyclosporin-A, Azathioprine, and prophylactic Antithymocyte Globuline (ATG).
Observation:
- Two post-HTX patients presented with heart failure four months after surgery.
- Endomyocardial biopsies revealed mild rejection (Billingham stage I) and interstitial fibrosis.
- Clinical signs and biopsy results suggested a potential complication beyond standard rejection.
Findings:
- Cyclosporin-A treatment was discontinued and replaced with Prednisolone and Azathioprine.
- Acute heart failure was managed with catecholamines and diuretics.
- Both patients showed significant recovery within three weeks of treatment modification.
Implications:
- Cyclosporin-A may induce a vascular process leading to heart failure in transplant recipients.
- This case suggests a potential pathogenic role for Cyclosporin-A in post-transplant cardiac dysfunction.
- Careful monitoring for drug-induced complications, distinct from rejection, is crucial in heart transplant management.
Abstract:
Two patients suffering from dilated Cardiomyopathy (CMP) had to undergo orthotopic heart transplantation (HTX). In both cases, the postoperative period was without any complications. The immunosuppression consisted of Cyclosporin-A and Azathioprine including a one week prophylactic treatment with Antithymocyte Globuline (ATG). Four months postoperatively, they developed clinical signs of heart failure. The endomyocardial biopsies showed rejection at stage I according to Billingham's grading plus a fine interstitial fibrosis. Therefore, the Cyclosporin treatment was suspended and replaced by conventional immunosuppression consisting of Prednisolone and Azathioprine. Acute heart failure was managed by catecholamines in combination with aggressive diuretic therapy. After three weeks, both patients recovered. 12 weeks later, one died because of an acute rejection episode. The other is in good condition, with conventional immunosuppression at the present time. A vascular process caused by Cyclosporin-A as the pathogenic mechanism is considered. The absence of rejection signs in the biopsies as well as the remarkable improvement of heart failure after withdrawal of Cyclosporin-A support this possibility.